Becton Dickinson (NYSE:BDX) announced today that orders have surpassed 1 billion for syringes and needles needed to deliver COVID-19 vaccines.
The Franklin Lakes, N.J.–based medtech giant now has commitments from governments in countries including the United States, Australia, Belgium, Canada, Germany, Netherlands, Saudi Arabia, Spain and the United Kingdom.
BD has already delivered more than 300 million of the injection devices, with the rest expected to be delivered by the end of 2021. Discussions with governments continue for more orders in late 2021 and early 2022.
“This milestone is more than just a number – it represents hundreds of millions of people around the world, such as frontline workers and at-risk loved ones who will now be able to receive a vaccination the moment vaccines are available,” said Rick Byrd, president of Medication Delivery Solutions at BD.
Elizabeth Woody, BD’s SVP of public affairs, told Drug Delivery Business News earlier in the week that the company is presently using its current global manufacturing infrastructure in order to meet demand, with expanded manufacturing in Nebraska coming on line in coming months. Here are more insights from Woody on how BD is tackling the challenge.